BioSpace News Archive

Care Bridge International, a data analytics corporation, today announced a new COVID-19 Calculator that estimates the true exposure of medical treatment and costs related to COVID-19 claims

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for its full year ended December 31, 2019, as well as select corporate highlights.

One Medical (Nasdaq: ONEM) announced today the expansion of its virtual care offerings with Remote Visits, scheduled video appointments with a primary care provider, and Mindset by One Medical, a virtual therapy and coaching program to support behavioral health.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has shifted part of its production to provide medical-grade hand sanitizers to hospitals and health care workers to assist in the ongoing fight against COVID-19. USC began manufacturing sanitizers after the Food and Drug Administration (FDA) issued guidance enabling FDA-registered outsourcing facilit

Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, “Atopidine”. The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl E

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market. Breast Cancer and Colorectal Cancer tests commissioned, and sales commenced First Quarter 2020 with over 100 test kits distributed. Early data generated from tests identified a number of high-risk individuals leading to personalised care plans designed for early detection Consumer Initiated Tes

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the Company’s common stock, at a purchase price of $1.60 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 3

Heska Corporation today announces the completion of the acquisition of scil animal care company GmbH (“scil”) from Covetrus, Inc

Macromoltek, Inc. today announced computational de novo design capability to speed up the development of human monoclonal antibodies for the potential treatment of COVID-19.

The proton center at Huntsman Cancer Institute at the University of Utah will be the first in the Mountain West.